VSRF LIVE 100th Episode Tomorrow: Time To Sue Pfizer?
With Covid Litigation Attorneys Tricia Lindsay and Jeff Childers
VSRF LIVE
Thursday, October 26
7pm Eastern | 4pm Pacific
Live stream on Rumble
Important Note: VSRF Live is exclusively on Rumble - NO MORE ZOOM
Join us for our 100th episode of VSRF LIVE this Thursday. We will directly address the controversy surrounding my tweet about the SV40 Plasmidgate adulteration and Pfizer litigation, which sparked a fierce debate. I will be speaking with two exceptional legal minds in the COVID litigation arena, Tricia Lindsay and Jeff Childers, both distinguished speakers at the first Covid Litigation Conference and our upcoming Covid Litigation Conference II.
Is the SV40 adulteration, which Pfizer did not disclose to regulators in America, a routine manufacturing technique (as Alex Berenson argues), or does it provide the grounds to vitiate the PREP ACT and finally hold Pfizer accountable for COVID-19 vaccine injuries and deaths?
Moreover, we will not just be addressing this question from a technical perspective. We will also address it by discussing the pressing concerns faced by those affected by vaccine injuries and losses. What steps can they take in light of these revelations? How can we offer support to the lawyers passionately working in this space? These are the critical questions we will answer tomorrow night on VSRF LIVE as we build pathways toward justice and accountability.
At VSRF, we are dedicated to this cause, and one of our initiatives is the upcoming Covid Litigation Conference II, scheduled for March 7-8th in Las Vegas. This conference is not just an event; it's a platform where legal minds unite to strategize, collaborate, and initiate legal actions against unjust Covid policies. I urge you to attend and encourage any attorneys you know to join us. The more Covid-related lawsuits we initiate, the harder it becomes for these policies to resurface in the future
However, to fuel initiatives like the Covid Litigation Conference II, VSRF needs your support. We will air our 100th VSRF Live episode this week, a testament to the journey we have embarked on together. Your backing has brought us this far, and your continued support is vital for our continued success. Please consider contributing a monthly donation to keep VSRF running. Your support is not just a contribution; it's an investment in the fight against the corrupt elite, ensuring that we can keep the lights on and continue our mission to reclaim our rights and freedoms.
You can donate at VacSafety.org/donate
Thank you for being an integral part of this movement. Together, we will win.
Join us tonight and bring a friend. Please also share widely! Just re-post any of these links:
One more thing, with regards to using the term "adulteration" within a legal context... it may not be a good idea, take a look:
Drug & Device Law
On Expert “Adulteration” and “Misbranding” Opinions
https://www.druganddevicelawblog.com/2022/03/on-expert-adulteration-and-misbranding-opinions.html
[Finally, [the expert’s] opinions that the [the drug] was “misbranded” or “adulterated” are inadmissible legal conclusions. The Federal Rules of Evidence do not permit an expert to render conclusions of law, because such testimony cannot properly assist the jury in understanding the evidence or determining a fact in issue. ]
[[The expert’s] opinions that [the drug] was adulterated, misbranded, or false and misleading under the FDA regulations should be excluded as inadmissible legal conclusions.]
If you are going to do that Steve, I recommend that some members of your team read this book, you may needed:
Drug and Medical Device Product Liability Deskbook
https://www.lawcatalog.com/drug-and-medical-device-product-liability-deskbook-12.html
Description:
[FDA-regulated products now account for an estimated one-fifth of overall economic activity in the U.S. They have also been the focus of a litigation explosion. This timely guide covers all aspects of litigation involving drugs, medical devices, vaccines and other FDA-regulated prescription products.
The Drug and Medical Device Product Liability Deskbook includes: detailed coverage of: warning-related claims and defenses; other information-based theories; strict liability; FDA-related per se liability; preemption of common law tort claims by the Food, Drug & Cosmetic Act and FDA regulations; class actions in drug and medical device litigation; theories of liability asserted against entities other than manufacturers; practical issues involving litigation management; the use of expert witnesses; and many other important topics. The authors include practical coverage of “what a litigator needs to know about the FDA.” You'll also find out how plaintiffs and defendants can enhance their chances for success before litigation even commences.
Book #00674; looseleaf, one volume, 1,158 pages; published in 2004, updated as needed; no additional charge for updates during your subscription. Looseleaf print subscribers receive supplements. The online edition is updated automatically. ISBN: 978-1-58852-121-7.]